Besides, the in vivo study also demonstrated that such nanovaccines enhanced the population of antigen-specific CD8+ T cells, which significantly suppressed tumor growth as well as improved the survival rate of tumor-bearing mice. The gene discussed is CD8A; the disease is neoplasm.